Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in lung fibrosis, it has been suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis. METHODS: In a 12-month, phase 2 trial, we assessed the efficacy and safety of four different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity. RESULTS: A total of 432 patients underwent randomization to receive one of four doses of BIBF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo. In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 liters per year, as compared with 0.19 liters per year in the placebo group, a 68.4% reduction in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure). This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007). Gastrointestinal symptoms (which led to more discontinuations in the group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00514683 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Bayesian approach incorporated dynamic borrowing of historical placebo data from several external IPF trials, including the ASCEND, INPULSIS, and TOMORROW studies (Figures E2 and E3).2,3,13”
From Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial (2026) · cites this paper as [13]
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationBois, R. M. D., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1179oc · Cited by 465
Self-citation
Cited by
Items 101–200 of 1,000
Pérez-Bogerd, S., Wuyts, W. A., Barbier, V., Demeyer, H., Muylem, A. V., Janssens, W., & Troosters, T. (2018) · Respiratory Research · doi:10.1186/s12931-018-0884-y · Cited by 143
Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis
Brown, S.-A. W., Dobelle, M., Padilla, M. L., Agovino, M., Wisnivesky, J. P., Hashim, D., & Boffetta, P. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201807-481oc · Cited by 142
Lee, T.-H., Yeh, C., Lee, Y.-T., Shih, Y.-C., Chen, Y.-T., Hung, C., You, M.-Y., Wu, P., Shentu, T., Huang, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18047-x · Cited by 135
Dysregulation of metabolic pathways in pulmonary fibrosis
Rajesh, R., Atallah, R., & Bärnthaler, T. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108436 · Cited by 139
Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches
Glass, D. S., Grossfeld, D. J., Renna, H. A., Agarwala, P., Spiegler, P. A., Kasselman, L. J., Glass, A. D., DeLeon, J. R., & Reiss, A. B. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.04.002 · Cited by 138
Angiogenesis in Pulmonary Fibrosis
Hanumegowda, C., Farkas, L., & Kolb, M. R. J. (2012) · CHEST Journal · doi:10.1378/chest.11-1962 · Cited by 134
Tyrosine kinase signaling in fibrotic disorders
Beyer, C., & Distler, J. H. W. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.06.008 · Cited by 126
Targeting FGFR for cancer therapy
Zhang, P., Yue, L., Leng, Q., Chen, C., Gan, C., Ye, T., & Cao, D. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01558-1 · Cited by 139
Normativa sobre el diagnóstico y tratamiento de la fibrosis pulmonar idiopática
Xaubet, A., Ancochea, J., Bollo, E., Fernández‐Fabrellas, E., Franquet, T., Molina‐Molina, M., Montero, M. A., & Serrano‐Mollar, A. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.03.011 · Cited by 138
The prognostic value of HRCT in myositis-associated interstitial lung disease
Tanizawa, K., Handa, T., Nakashima, R., Kubo, T., Hosono, Y., Aihara, K., Ikezoe, K., Watanabe, K., Taguchi, Y., Hatta, K., et al. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.01.014 · Cited by 131
Idiopathic pulmonary fibrosis: An update
Spagnolo, P., Sverzellati, N., Rossi, G., Cavazza, A., Tzouvelekis, A., Crestani, B., & Vancheri, C. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.982165 · Cited by 120
Japanese guideline for the treatment of idiopathic pulmonary fibrosis
Homma, S. A., Bando, M., Azuma, A., Sakamoto, S., Sugino, K., Ishii, Y., Izumi, S., Inase, N., Inoue, Y., Ebina, M., et al. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.03.003 · Cited by 133
Rheumatoid Arthritis (RA) associated interstitial lung disease (ILD)
O’Dwyer, D. N., Armstrong, M. E., Cooke, G., Dodd, J. D., Veale, D. J., & Donnelly, S. C. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.07.004 · Cited by 122
Myllärniemi, M., & Kaarteenaho, R. (2015) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v2.26385 · Cited by 117
Kalchiem‐Dekel, O., Galvin, J. R., BURKE, A. P., Atamas, S. P., & Todd, N. W. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120476 · Cited by 128
Nintedanib: First Global Approval
McCormack, P. L. (2014) · Drugs · doi:10.1007/s40265-014-0335-0 · Cited by 123
Noskovičová, N., Petřek, M., Eickelberg, O., & Heinzelmann, K. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0294tr · Cited by 110
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
Khor, Y. H., Ng, Y., Barnes, H., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2020) · European Respiratory Review · doi:10.1183/16000617.0158-2019 · Cited by 127
Wuyts, W. A., Kolb, M., Stowasser, S., Stansen, W., Huggins, J. T., & Raghu, G. (2016) · Lung · doi:10.1007/s00408-016-9912-1 · Cited by 119
Self-citationA novel computational approach for drug repurposing using systems biology
Peyvandipour, A., Saberian, N., Shafi, A., Donato, M., & Drăghici, S. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty133 · Cited by 125
Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease
Kida, Y., Tchao, B. N., & Yamaguchi, I. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2430-y · Cited by 117
Optimizing quality of life in patients with idiopathic pulmonary fibrosis
van Manen, M. J. G., Geelhoed, J. J. M., Tak, N. C., & Wijsenbeek, M. S. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816686743 · Cited by 124
Use of animal models in IPF research
Carrington, R., Jordan, S., Pitchford, S. C., & Page, C. P. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.07.002 · Cited by 115
Richeldi, L., Kreuter, M., Selman, M., Crestani, B., Kirsten, A.-M., Wuyts, W. A., Xu, Z., Bernois, K., Stowasser, S., Quaresma, M., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2016-209701 · Cited by 103
Self-citationThe Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
Diamantopoulos, A., Wright, E., Vlahopoulou, K., Cornic, L., Schoof, N., & Maher, T. M. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0631-8 · Cited by 122
Richeldi, L., Cottin, V., Flaherty, K. R., Kolb, M., Inoue, Y., Raghu, G., Taniguchi, H., Hansell, D. M., Nicholson, A. G., Le Maulf, F., et al. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.04.011 · Cited by 104
Self-citationTherapeutic Targeting of Src Kinase in Myofibroblast Differentiation and Pulmonary Fibrosis
Hu, M., Che, P., Han, X., Cai, G., Liu, G., Antony, V. B., Luckhardt, T., Siegal, G. P., Zhou, Y., Liu, R.-M., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216044 · Cited by 113
Oda, K., Ishimoto, H., Yatera, K., Naito, K., Ogoshi, T., Yamasaki, K., Imanaga, T., Tsuda, T., Nakao, H., Kawanami, T., et al. (2014) · Respiratory Research · doi:10.1186/1465-9921-15-10 · Cited by 106
Sheth, J. S., Belperio, J. A., Fishbein, M. C., Kazerooni, E. A., Lagstein, A., Murray, S., Myers, J. L., Simon, R. H., Sisson, T. H., Sundaram, B., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.09.028 · Cited by 116
Self-citationThe diagnosis of idiopathic pulmonary fibrosis: current and future approaches
Martinez, F. J., Chisholm, A., Collard, H. R., Flaherty, K. R., Myers, J., Raghu, G., Walsh, S. L. F., White, E. S., & Richeldi, L. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30325-3 · Cited by 107
Self-citationMaher, T. M., Stowasser, S., Nishioka, Y., White, E. S., Cottin, V., Noth, I., Selman, M., Rohr, K. B., Michael, A., Ittrich, C., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30255-3 · Cited by 106
Self-citationRaghu, G., Ghazipura, M., Fleming, T. R., Aronson, K. I., Behr, J., Brown, K. K., Flaherty, K. R., Kazerooni, E. A., Maher, T. M., Richeldi, L., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2213so · Cited by 92
Self-citationSatō, T., Kondo, H., Watanabe, A., Nakajima, J., Niwa, H., Horio, H., Okami, J., Okumura, N., Sugio, K., Teramukai, S., et al. (2014) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-014-0487-6 · Cited by 110
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
Rochwerg, B., Neupane, B., Zhang, Y., Garcia, C. C., Raghu, G., Richeldi, L., Brozek, J., Beyene, J., & Schünemann, H. (2016) · BMC Medicine · doi:10.1186/s12916-016-0558-x · Cited by 101
“Richeldi 2011 [35] Multicenter (92) Worldwide n = 428 Yes FVC >50 % predicted DLCO 30–79 % predicted Nintedanib 12 months Low Nintedanib 25/ 343 Placebo 9/85 90/343 26/85 Boehringer Ingelheim”
BackgroundSelf-citationPathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis
Loomis-King, H. A., Flaherty, K. R., & Moore, B. B. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.03.015 · Cited by 113
Self-citationA Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis
Rosas, I. O., Goldberg, H. J., Collard, H. R., El‐Chemaly, S., Flaherty, K. R., Hunninghake, G. M., Lasky, J. A., Lederer, D. J., Machado, R. F., Martínez, F. J., et al. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.09.052 · Cited by 101
Self-citationKato, M., Sasaki, S., Nakamura, T., Kurokawa, K., Yamada, T., Ochi, Y., Ihara, H., Takahashi, F., & Takahashi, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-48593-4 · Cited by 106
Guzy, R. D., Stoilov, I., Elton, T. J., Mecham, R. P., & Ornitz, D. M. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0184oc · Cited by 95
Richeldi, L., Varone, F., Bergna, M., de Andrade, J., Falk, J., Hallowell, R., Jouneau, S., Kondoh, Y., Morrow, L., Randerath, W., et al. (2018) · European Respiratory Review · doi:10.1183/16000617.0074-2018 · Cited by 95
Self-citationLung transplantation for interstitial lung disease
Kapnadak, S. G., & Raghu, G. (2021) · European Respiratory Review · doi:10.1183/16000617.0017-2021 · Cited by 91
Self-citationTreatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review
Iqbal, K., & Kelly, C. A. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15612250 · Cited by 106
Idiopathic pulmonary fibrosis and cancer: do they really look similar?
Vancheri, C. (2015) · BMC Medicine · doi:10.1186/s12916-015-0478-1 · Cited by 94
Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis
Perrot, C. Y., Karampitsakos, Τ., & Herazo‐Maya, J. D. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00302.2023 · Cited by 103
Swigris, J. J., Esser, D., Conoscenti, C. S., & Brown, K. K. (2014) · Health and Quality of Life Outcomes · doi:10.1186/s12955-014-0124-1 · Cited by 90
Self-citationAono, Y., Kishi, M., Yokota, Y., Azuma, M., Kinoshita, K., Takezaki, A., Sato, S., Kawano, H., Kishi, J., Goto, H., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0455oc · Cited by 98
Current approaches to the management of idiopathic pulmonary fibrosis
Raghu, G., & Richeldi, L. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.05.017 · Cited by 90
Self-citationThe St. George’s Respiratory Questionnaire as a prognostic factor in IPF
Furukawa, T., Taniguchi, H., Ando, M., Kondoh, Y., Kataoka, K., Nishiyama, O., Johkoh, T., Fukuoka, J., Sakamoto, K., & Hasegawa, Y. (2017) · Respiratory Research · doi:10.1186/s12931-017-0503-3 · Cited by 99
Nintedanib for the treatment of idiopathic pulmonary fibrosis
Varone, F., Sgalla, G., Iovene, B., Bruni, T., & Richeldi, L. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1425681 · Cited by 98
Self-citationS2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose
Behr, J., Günther, A., Ammenwerth, W., Bittmann, I., Bonnet, R. B., Buhl, R., Eickelberg, O., Ewert, R., Gläser, S., Gottlieb, J., et al. (2013) · Pneumologie · doi:10.1055/s-0032-1326009 · Cited by 110
Self-citationUmemura, Y., Mitsuyama, Y., Minami, K., Nishida, T., Watanabe, A., Okada, N., Yamakawa, K., Nochioka, K., & Fujimi, S. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.055 · Cited by 103
Staging of idiopathic pulmonary fibrosis: past, present and future
Kolb, M., & Collard, H. R. (2014) · European Respiratory Review · doi:10.1183/09059180.00002114 · Cited by 87
Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis
Murray, L. A., Habiel, D. M., Hohmann, M., Camelo, A., Shang, H., Zhou, Y., Coelho, A. L., Peng, X., Gulati, M., Crestani, B., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92192 · Cited by 85
Marchioni, A., Tonelli, R., Ball, L., Fantini, R., Castaniere, I., Cerri, S., Luppi, F., Malerba, M., Pelosi, P. P., & Clini, E. M. (2018) · Critical Care · doi:10.1186/s13054-018-2002-4 · Cited by 93
Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Jafarinezhad, A., & YektaKooshali, M. H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202360 · Cited by 97
Redente, E. F., Aguilar, M., Black, B. P., Edelman, B., Bahadur, A. N., Humphries, S. M., Lynch, D. A., Wollin, L., & Riches, D. W. H. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00304.2017 · Cited by 95
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy
Spagnolo, P., Maher, T. M., & Richeldi, L. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.04.005 · Cited by 94
Self-citationEfficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
Takeda, Y., Tsujino, K., Kijima, T., & Kumanogoh, A. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s37233 · Cited by 87
Lin, S., Mao, R., Qian, C., Bettenworth, D., Wang, J., Li, J., Bruining, D. H., Jairath, V., Feagan, B. G., Chen, M., et al. (2021) · Physiological Reviews · doi:10.1152/physrev.00005.2021 · Cited by 90
Emerging role of immune cells as drivers of pulmonary fibrosis
Mutsaers, S. E., Miles, T., Prêle, C. M., & Hoyne, G. F. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108562 · Cited by 96
Outcomes in idiopathic pulmonary fibrosis: A meta-analysis from placebo controlled trials
Atkins, C., Loke, Y. K., & Wilson, A. M. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.11.007 · Cited by 93
Myofibroblast Differentiation and Enhanced Tgf-B Signaling in Cystic Fibrosis Lung Disease
Harris, W. T., Kelly, D. R., Zhou, Y., Wang, D., MacEwen, M. W., Hagood, J. S., Clancy, J. P., Ambalavanan, N., & Sorscher, E. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070196 · Cited by 94
Kondoh, Y., Taniguchi, H., Ebina, M., Azuma, A., Ogura, T., Taguchi, Y., Suga, M., Takahashi, H., Nakata, K., Sugiyama, Y., et al. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.04.005 · Cited by 88
Genetic determinants of pulmonary fibrosis: evolving concepts
Spagnolo, P., Grünewald, J., & du Bois, R. M. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70047-5 · Cited by 89
He, C., Larson-Casey, J. L., Gu, L., Ryan, A. J., Murthy, S., & Carter, A. B. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0183oc · Cited by 84
Rivera‐Ortega, P., Hayton, C., Blaikley, J., Leonard, C. T., & Chaudhuri, N. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618800618 · Cited by 90
Seibold, J. R., Maher, T. M., Highland, K. B., Assassi, S., Azuma, A., Hummers, L. K., Costabel, U., von Wangenheim, U., KOHLBRENNER, V. M., Gahlemann, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217331 · Cited by 87
Self-citationTsou, P., Haak, A. J., Khanna, D., & Neubig, R. R. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00060.2014 · Cited by 96
Gas6/TAM System: A Key Modulator of the Interplay between Inflammation and Fibrosis
Bellan, M., Cittone, M. G., Tonello, S., Rigamonti, C., Castello, L. M., Gavelli, F., Pirisi, M., & Sainaghi, P. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205070 · Cited by 85
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells
Nishijima, N., Seike, M., Soeno, C., Chiba, M., Miyanaga, A., Noro, R., Sugano, T., Matsumoto, M., Kubota, K., & Gemma, A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3331 · Cited by 82
Faverio, P., Giacomi, F. D., Sardella, L., Fiorentino, G., Carone, M., Salerno, F. G., Ora, J., Rogliani, P., Pellegrino, G. M., Papa, G. F. S., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0643-3 · Cited by 89
Hu, Y., Wang, L.-S., Wei, Y., Du, S.-S., Du, Y., He, X., Li, N., Zhou, Y., Li, Q., Su, Y., et al. (2015) · CHEST Journal · doi:10.1378/chest.15-1145 · Cited by 88
Self-citationMargaritopoulos, G., Vasarmidi, E., & Antoniou, K. (2016) · Core Evidence · doi:10.2147/ce.s76549 · Cited by 81
Cerri, S., Monari, M., Guerrieri, A., Donatelli, P., Bassi, I., Garuti, M., Luppi, F., Betti, S., Bandelli, G., Carpano, M., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.105803 · Cited by 76
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial
Lancaster, L., Cottin, V., Ramaswamy, M., Wuyts, W. A., Jenkins, R. G., Scholand, M. B., Kreuter, M., Valenzuela, C., Ryerson, C. J., Goldin, J., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202403-0636oc · Cited by 80
“Gastrointestinal adverse events, including diarrhea, are common adverse reactions in patients treated with nintedanib or pirfenidone (10, 12 – 14 , 16 ).”
BackgroundResultSelf-citationReal-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Brunnemer, E., Wälscher, J., Ehlers-Tenenbaum, S., Hausmanns, J., Schulze, K., Seiter, M., Heußel, C. P., Warth, A., Herth, F. J. F., & Kreuter, M. (2018) · Respiration · doi:10.1159/000485933 · Cited by 83
Regulation and Relevance of Myofibroblast Responses in Idiopathic Pulmonary Fibrosis
Moore, M. W., & Herzog, E. L. (2013) · Current Pathobiology Reports · doi:10.1007/s40139-013-0017-8 · Cited by 89
Bettenworth, D., & Rieder, F. (2014) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-7-5 · Cited by 85
Idiopathic Pulmonary Fibrosis: Treatment and Prognosis
Fujimoto, H., Kobayashi, T., & Azuma, A. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s23321 · Cited by 88
Takezaki, A., Tsukumo, S., Setoguchi, Y., Ledford, J. G., Goto, H., Hosomichi, K., Uehara, H., Nishioka, Y., & Yasutomo, K. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182351 · Cited by 83
Homocysteine induces endothelial dysfunction via inhibition of arginine transport.
Jin, L., Caldwell, R. B., Li-Masters, T., & Caldwell, R. W. (2007) · PubMed · Cited by 95
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Yoon, H.-Y., Park, S., Kim, D. S., & Song, J. W. (2018) · Respiratory Research · doi:10.1186/s12931-018-0907-8 · Cited by 78
Self-citationBowman, W. S., Echt, G. A., & Oldham, J. M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.680997 · Cited by 77
Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis
Su, T., Kao, J., & Liu, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150610578 · Cited by 80
Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF
Farrand, E. D., Vittinghoff, E., Ley, B., Butte, A. J., & Collard, H. R. (2019) · Respirology · doi:10.1111/resp.13753 · Cited by 78
Hetzel, J., Wells, A. U., Costabel, U., Colby, T. V., Walsh, S. L. F., Verschakelen, J., Cavazza, A., Tomassetti, S., Ravaglia, C., Böckeler, M., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01520-2019 · Cited by 78
Self-citationNintedanib in the treatment of idiopathic pulmonary fibrosis
Mazzei, M. E., Richeldi, L., & Collard, H. R. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815579365 · Cited by 74
Self-citationMesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis
Tzouvelekis, A., Toonkel, R. L., Karampitsakos, Τ., Medapalli, K., Ninou, I., Aidinis, V., Bouros, D. E., & Glassberg, M. K. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00142 · Cited by 81
Bargagli, E., Piccioli, C., Rosi, E., Torricelli, E., Turi, L., Piccioli, E., Pistolesi, M., Ferrari, K., & Voltolini, L. (2018) · Pulmonology · doi:10.1016/j.pulmoe.2018.06.003 · Cited by 78
Lipid nanoparticle-mediated mRNA delivery in lung fibrosis
Massaro, M., Wu, S., Baudo, G., Liu, H., Collum, S. D., Lee, H., Stigliano, C., Segura-Ibarra, V., Karmouty‐Quintana, H., & Blanco, E. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106370 · Cited by 80
Osterholzer, J. J., Christensen, P. J., Lama, V. N., Horowitz, J. C., Hattori, N., Subbotina, N., Cunningham, A. K., Lin, Y., Murdock, B. J., Morey, R. E., et al. (2012) · The Journal of Pathology · doi:10.1002/path.3992 · Cited by 80
Dasatinib Reduces Lung Inflammation and Fibrosis in Acute Experimental Silicosis
Cruz, F. F., Horta, L. F. B., Maia, L. D. A., Lopes-Pacheco, M., Silva, A. B. D., Morales, M. M., Gonçalves-de-Albuquerque, C. F., Takiya, C. M., de Castro-Faria-Neto, H. C., & Rocco, P. R. M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147005 · Cited by 75
Mesenchymal stem cells in the treatment of chronic lung disease
Wecht, S., & Rojas, M. (2016) · Respirology · doi:10.1111/resp.12911 · Cited by 77
Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis
Cordier, J.-F., & Cottin, V. (2013) · European Respiratory Journal · doi:10.1183/09031936.00027913 · Cited by 78
Collum, S. D., Amione‐Guerra, J., Cruz-Solbes, A. S., DiFrancesco, A., Hernandez, A. M., Hanmandlu, A., Youker, K. A., Guha, A., & Karmouty‐Quintana, H. (2017) · Canadian Respiratory Journal · doi:10.1155/2017/1430350 · Cited by 88
O'Brien, E. C., Durheim, M. T., Gamerman, V., Garfinkel, S., Anstrom, K. J., Palmer, S. M., & Conoscenti, C. S. (2016) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2015-000108 · Cited by 75
Current and novel drug therapies for idiopathic pulmonary fibrosis
Maher, T. M., & Adamali, H. I. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s29928 · Cited by 89
Human Epidermal Growth Factor Receptor Signaling in Acute Lung Injury
Finigan, J. H., Downey, G. P., & Kern, J. A. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0100tr · Cited by 78
Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
Muhic, A., Poulsen, H. S., Mau‐Sørensen, M., Grunnet, K., & Lassen, U. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1009-y · Cited by 75
Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease
Liu, F., Wang, L., Qi, H., Wang, J., Wang, Y., Jiang, W., Xu, L., Liu, N., & Zhuang, S. (2017) · Clinical Science · doi:10.1042/cs20170134 · Cited by 76
RetractedThe Management of Patients With Idiopathic Pulmonary Fibrosis
Spagnolo, P., Tzouvelekis, A., & Bonella, F. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00148 · Cited by 72
Metadata
- Authors
- Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Klüglich, M., & du Bois, R. M.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Ruhrlandklinik (DE)
- Asan Medical Center (KR)
- Royal Brompton Hospital (GB)
- Michigan Medicine (US)
- Duke Medical Center (US)
- University of Washington (US)
- Boehringer Ingelheim (France) (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-09-22
- Volume
- 365
- Issue
- 12
- Pages
- 1079-1087
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152974152
- Cited by
- 1,157
- References
- 22
- Citations by year
- 2026: 32 · 2025: 50 · 2024: 79 · 2023: 74 · 2022: 83 · 2021: 86 · 2020: 73 · 2019: 72 · 2018: 91 · 2017: 102 · 2016: 88 · 2015: 100 · 2014: 71 · 2013: 80 · 2012: 61
- FWCI
- 60.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, nintedanib, tyrosine kinase inhibitors, forced vital capacity decline, lung fibrosis progression, acute exacerbation, quality of life, gastrointestinal adverse effects, liver aminotransferases, dose comparison, St George's Respiratory Questionnaire, total lung capacity, drug safety and efficacy
- MeSH terms
- Adult, Aged, Alanine Transaminase, Aspartate Aminotransferases, Enzyme Inhibitors, Female, Humans, Indoles, Liver, Male, Middle Aged, Protein-Tyrosine Kinases, Vital Capacity, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.